Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Baxter International Inc Market Cap
From what 15 stock analysts predict, the share price for Baxter International Inc (BAX) might increase by 25.72% in the next year. This is based on a 12-month average estimation for BAX. Price targets go from $30 to $62. The majority of stock analysts believe BAX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Baxter International Inc has a total of 15 Wall St Analyst ratings. There are 3 buy ratings, 11 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Baxter International Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of BAX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Rick Wise Stifel | Buy | $38 | Maintains | Nov 11, 2024 |
| Joanne Wuensch Citigroup | Neutral | $40 | Maintains | Oct 1, 2024 |
| David Roman Goldman Sachs | Neutral | $40 | Maintains | Aug 8, 2024 |
| Larry Biegelsen Wells Fargo | Equal-Weight | $40 | Maintains | Aug 7, 2024 |
| Robbie Marcus JP Morgan | Neutral | $42 | Maintains | Aug 7, 2024 |
| Patrick Wood Morgan Stanley | Underweight | $30 | Downgrade | Jul 15, 2024 |
Citigroup | Neutral | Maintains | Jul 11, 2024 | |
| Joanne Wuensch Citigroup | Neutral | $37 | Maintains | Jul 10, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $45 | Maintains | Jul 2, 2024 |
| David Roman Goldman Sachs | Neutral | $36 | Initiates | May 30, 2024 |
| Joanne Wuensch Citigroup | Neutral | $38 | Maintains | May 22, 2024 |
| Joshua Jennings TD Cowen | Hold | $40 | Downgrade | May 10, 2024 |
| Joanne Wuensch Citigroup | Neutral | $44 | Maintains | Apr 3, 2024 |
| Travis Steed B of A Securities | Neutral | $45 | Maintains | Mar 5, 2024 |
| Matt Miksic Barclays | Overweight | $54 | Maintains | Feb 12, 2024 |
| Robbie Marcus JP Morgan | Neutral | $44 | Maintains | Feb 9, 2024 |
| Patrick Wood Morgan Stanley | Equal-Weight | $39 | Maintains | Dec 4, 2023 |
| Robbie Marcus JP Morgan | Neutral | $36 | Maintains | Oct 31, 2023 |
| Joanne Wuensch Citigroup | Neutral | $45 | Maintains | Aug 21, 2023 |
Barclays | Overweight | Maintains | Aug 1, 2023 |
When did it IPO
1981
Staff Count
60,000
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Jose E. Almeida
Market Cap
$16.05B
In 2023, BAX generated $14.81B in revenue, which was a increase of 2.12% from the previous year. This can be seen as a signal that BAX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Baxter International has resumed all dialysis solution production at its North Carolina facility after interruptions due to hurricane-related flooding.
Why It Matters - Baxter's resumption of dialysis solution production signals recovery from disruptions, potentially stabilizing supply and supporting revenue, which is crucial for investor confidence and stock performance.
Fri, 29 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - BALY, BAX, and CENTA have been assigned a Zacks Rank of #5 (Strong Sell) as of November 29, 2024.
Why It Matters - Zacks Rank #5 indicates a bearish outlook for BALY, BAX, and CENTA, suggesting potential declines in stock prices, which may influence investor sentiment and decisions.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Baxter International Inc. (NYSE:BAX) will present at the Evercore HealthCONx Conference on December 5, 2024. CFO Joel Grade will speak at 9:10 a.m. ET; webcast available for replay until June 3, 2025.
Why It Matters - Baxter's presentation at a major health conference could impact stock performance, influencing investor sentiment and potentially affecting market valuation based on new insights shared.
Thu, 21 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - BATRA, BAX, and BRKR have been assigned a Zacks Rank #5 (Strong Sell) as of November 21, 2024.
Why It Matters - The addition of BATRA, BAX, and BRKR to the Zacks Rank #5 (Strong Sell) indicates potential underperformance, signaling investors to reassess their positions in these stocks.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Baxter International Inc. (NYSE:BAX) will present at the Jefferies London Healthcare Conference on November 20, 2024, at 11:00 a.m. GMT. A live webcast will be available on their website.
Why It Matters - Baxter's presentation at the Jefferies conference could signal strategic updates or financial insights, influencing investor sentiment and stock performance.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Baxter International Inc. declared a quarterly cash dividend of $0.17 per share, payable on Jan. 2, 2025. The annual dividend rate is now $0.68 per share, reflecting changes due to a planned divestiture.
Why It Matters - Baxter's dividend announcement reflects financial stability and a commitment to returning value to shareholders, signaling confidence amid upcoming strategic changes.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
